Dr. Silbermann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd., OC14HO
Portland, OR 97239
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2008 - 2011
University of RochesterResidency, Internal Medicine, 2004 - 2007
The Warren Alpert Medical School of Brown UniversityClass of 2004
Certifications & Licensure
ID State Medical License 2021 - 2026
WA State Medical License 2016 - 2026
OR State Medical License 2017 - 2025
IN State Medical License 2012 - 2017
PA State Medical License 2008 - 2012
NY State Medical License 2007 - 2008- American Board of Internal Medicine Hematology
Clinical Trials
- A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma Start of enrollment: 2014 Oct 01
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide Start of enrollment: 2023 Jan 18
Roles: Contact
- Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma Start of enrollment: 2022 Jun 14
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 384 citationsDaratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves
Blood. 2020-08-20 - 3 citationsDaratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves
Blood Cancer Journal. 2024-07-08 - 33 citationsAddition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final ana...Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
The Lancet. Haematology. 2023-10-01
Abstracts/Posters
- Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple MyelomaRebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Daratumumab Regimen Confers Health-Related Quality of Life Benefit in Multiple MyelomaDecember 11th, 2022- Multiple Myeloma: Choosing Your PathDecember 18th, 2020
OncLive® Presents Seven State of the Science Summit™ Meetings in MarchFebruary 26th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
